



## ASX Announcement

### SCHLESWIG-HOLSTEIN UNIVERSITY MEDICAL CENTRE SIGNS PURCHASE AGREEMENT WITH IMRICOR

**27 October 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR)** the global leader in iCMR guided cardiac ablation products, is pleased to announce the Schleswig-Holstein University Medical Centre (Universitätsklinikum Schleswig-Holstein, or UKSH), in Lübeck Germany, has signed a purchase agreement with Imricor. The Company is working with the Lübeck University Heart Centre, which is under the umbrella of UKSH, to schedule installation, training, and first procedures.

Professor Roland Tilz, Head of Electrophysiology at the Heart Centre commented: “I am very excited about our collaboration with Imricor. MRI guided ablation is a breakthrough technology. This technology enables active catheter tracking as well as passive real-time visualisation. It allows for lesion visualisation without potentially harmful fluoroscopy exposure to both the patient and the operator. In addition, it provides supplementary anatomic guidance to facilitate substrate guided ablation procedures.

“This is an immense advantage, compared to conventional 3D Mapping System guided ablation and has the potential to improve outcomes and reduce adverse events. I am very excited that we can start now with our first procedures in Lübeck.”

UKSH marks the fifth site Imricor has contracted in the past six weeks, bringing the total sites with signed agreements in place to eight.

The iCMR facilities at the Lübeck University Heart Centre are built around the latest Siemens 1.5T MAGNETOM Sola MR scanner.

Imricor’s Chair and CEO, Steve Wedan, said: “We are extremely excited to work with Professor Tilz and his truly outstanding team in Lübeck. Sites like the Lübeck Heart Centre at UKSH and physicians like Professor Tilz will lead the way as we continue to grow this new field and our installed based throughout Germany.

“Interestingly, some Lübeck team members can trace their experiences with Imricor back to Dresden earlier this year and even to our first pilot studies in Leipzig almost 10 years ago. This is the organic growth we envisioned, and we are thrilled to see iCMR guided ablations gaining traction, despite COVID.”

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS



## **Further Information**

### **Investors:**

Steve Wedan  
Executive Chair, President and CEO  
Email: [steve.wedan@imricor.com](mailto:steve.wedan@imricor.com)

### **Investors & Australian Media:**

Carrie Barrack  
Senior Advisor, Cato & Clive  
Email: [carrie@catoandclive.com](mailto:carrie@catoandclive.com)  
Mobile: +61 422 464 028

### **Rest of World Media:**

Nick Twohy  
Director of Marketing, Imricor  
Email: [nick.twohy@imricor.com](mailto:nick.twohy@imricor.com)  
Phone: +1 952 818 8407

## **About Imricor**

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

## **Imricor's Products**

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

## **Foreign Ownership Restrictions**

Imricor's CHESS Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.